About
Our mission
Governance
Partners
Science
Our Genome Engineering Platform
TALEN® Technology
In-House Manufacturing
Pipeline
Product Candidates
Investors
IR Overview
News
Press releases
Events and Webcasts
Presentations
Corporate presentations
Scientific presentations
Scientific publications
Corporate Governance
Board of Directors
Executive Committee
External Auditors
Governance Documents
General meetings
Financial Information
SEC filings
Financial statements
Voting Rights & Share Capital
Stock information
Shareholders Services
IR Inquiries
IR FAQ
Careers
Our culture
Job opportunities
Contact us
FR
Recherche
›
Investors
›
Scientific presentations
About
Our mission
Governance
Partners
Science
Our Genome Engineering Platform
TALEN® Technology
In-House Manufacturing
Pipeline
Product Candidates
Investors
IR Overview
News
Press releases
Events and Webcasts
Presentations
Corporate presentations
Scientific presentations
Scientific publications
Corporate Governance
Board of Directors
Executive Committee
External Auditors
Governance Documents
General meetings
Financial Information
SEC filings
Financial statements
Voting Rights & Share Capital
Stock information
Shareholders Services
IR Inquiries
IR FAQ
Careers
Our culture
Job opportunities
Contact us
FR
Scientific presentations
All
2026
2025
2024
2023
2022
2021
5
Jun 2023
07:27 E.S.T.
Non-viral DNA delivery associated to TALEN® gene editing leads to highly efficient correction of sickle cell mutation in long-term repopulating hematopoietic stem cells - ISCT 2023 – Poster Presentation
Download the PDF file
17
May 2023
22:55 E.S.T.
Expanding the Scope of Multiplex Engineering for Superior Generation of Efficient CAR T-cells – ASGCT 2023 – Poster Presentation
Download the PDF file
17
May 2023
18:30 E.S.T.
AMELI 01: A Phase I Trial of UCART123v1.2, an Anti CD123 Allogeneic CAR T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia – ASGCT 2023 – Oral Presentation
Download the PDF file
16
Apr 2023
12:00 E.S.T.
Deciphering the benefits of variable delivery routes and molecular armoring to enhance efficacy of MUC1-CAR T-cells in targeting triple-negative breast cancer – AACR 2023 – Poster presentation
Download the PDF file
Posts pagination
← PREV
1
2
Scientific publications
Discover Cellectis' scientific publications
Learn more